Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out

Once flush with part­ners for heart fail­ure drug ome­cam­tiv mecar­bil, Cy­to­ki­net­ics watched its long­time al­ly Am­gen flee last month over weak da­ta from a Phase III tri­al. Now, Cy­to­ki­net­ics’ last run­ning mate is hit­ting the ex­it — leav­ing ome­cam­tiv on an un­cer­tain path to mar­ket.

Les Lab­o­ra­toires Servi­er and In­sti­tut de Recherch­es In­ter­na­tionales Servi­er is pulling out of a sub­li­cense agree­ment for ome­cam­tiv that it struck with Am­gen back in 2016. The news comes ex­act­ly one month af­ter Am­gen un­veiled its own plans to walk away in May 2021 from a 14-year al­liance for ome­cam­tiv and the tens of mil­lions it spent de­vel­op­ing the con­tro­ver­sial drug, which it said “did not meet the high bar we had set for the pro­gram.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.